Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prevention of heart failure.

Tamara B Horwich1, Gregg C Fonarow

  • 1Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, 47-123 CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095-1679, USA.

Current Cardiology Reports
|April 19, 2002
PubMed
Summary

Preventing heart failure involves managing risk factors like diabetes and smoking, and treating asymptomatic left ventricular dysfunction (ALVD). Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are key for patients with ALVD.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A risk score for in-hospital death in patients admitted with ischemic or hemorrhagic stroke.

Journal of the American Heart Association·2013
Same author

American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 update: a scientific statement for public health practitioners, healthcare providers, and health policy makers.

Circulation·2013
Same author

Ultrafiltration in heart failure with cardiorenal syndrome.

The New England journal of medicine·2013
Same author

Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.

The American journal of medicine·2013
Same author

Renin-Angiotensin system antagonists and mortality in patients with heart failure.

JAMA·2013
Same author

Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure.

The American journal of medicine·2013

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Clinical Research

Background:

  • Heart failure prevalence, morbidity, and mortality are increasing.
  • Key risk factors include coronary artery disease, renal insufficiency, diabetes, and smoking.

Purpose of the Study:

  • To outline essential preventative strategies for heart failure.
  • To highlight the role of risk factor modification and early detection of asymptomatic left ventricular dysfunction (ALVD).

Main Methods:

  • Review of current medical literature and clinical guidelines.
  • Analysis of established and emerging preventative therapies.

Main Results:

  • Modification of risk factors is crucial for heart failure prevention.
  • Angiotensin-converting enzyme (ACE) inhibitor and beta-blocker therapies effectively prevent symptomatic progression in ALVD patients.
  • ACE inhibitors for all coronary artery disease and diabetic patients, clopidogrel in acute coronary syndromes, and avoiding specific antihypertensives are identified as preventative strategies.

Conclusions:

  • Proactive management of risk factors and early intervention for ALVD are vital for preventing heart failure.
  • Specific pharmacological interventions, including ACE inhibitors and beta-blockers, play a significant role in heart failure prevention strategies.

Related Experiment Videos